NCT07576309Completed
Repetitive GON Blockade for Menstrual Migraine
Perimenstrual Repetitive Greater Occipital Nerve Blockade for Menstrual Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
: The primary objective of this prospective, randomized, double-blind, placebo-controlled clinical trial is to evaluate whether repetitive bilateral greater occipital nerve (GON) blockade administered with a local anesthetic (0.5% bupivacaine) significantly reduces headache severity, attack duration, and the number of pain days in female patients with menstrual migraine compared to a placebo group (normal saline). Patients will receive injections twice a month for three months (seven days before the expected onset of menstruation and on the first day of menstruation).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 3 May 2026
- Start date
- 19 Oct 2024
- Primary completion date
- 30 May 2025
- Lead sponsor
- Saglik Bilimleri Universitesi
- Diseases
- Migraine
- NCT number
- NCT07576309
What you commit to
- Study type: Interventional
- Participants enrolled: 48
- From 19 Oct 2024 to the primary completion date, 30 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received an occipital nerve blockade within the last three months.
Other illness
- Presence of an additional primary or secondary headache disorder.
- Known hypersensitivity to local anesthetics.
- Presence of a significant neurological or systemic disease that could affect the outcome evaluation.
Other
- Diagnosis of chronic migraine.
- Pregnant or lactating.
Who the study is looking for
- Diagnosed with pure menstrual migraine or menstrually related migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) diagnostic criteria.
- A documented history of migraine attacks during the perimenstrual period (between days -2 and +3 relative to the onset of menstruation) in at least two of the last three menstrual cycles.
Age in the registry: 18 years to 50 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Saglik Bilimleri Universitesi Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.